Ford's (NYSE: F ) turnaround in North America has been one for the business history books. Since last fall, Ford has been working to apply the same strategy to its troubled European operation, which has lost billions.
But now there's some good news. In this video, Fool contributor John Rosevear looks at Ford's latest sales results from Europe. Signs suggest that Ford's turnaround is starting to take hold -- and that could do very good things for Ford's stock price.
Ford's turnaround in Europe is one of several good reasons to think that the Blue Oval still has big growth opportunities ahead. We've outlined all of those opportunities in detail in the Fool's premium Ford research service. If you're looking for some freshly updated guidance to Ford's prospects in coming years, you've come to the right place -- click here�to get started now.
5 Best Long Term Stocks To Buy Right Now: Array BioPharma Inc.(ARRY)
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases in North America, Europe, and the Asia Pacific. Its programs under development include ARRY-520, a kinesin spindle protein inhibitor in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie-2 dual inhibitor in Phase 1 clinical trial for patients with myelodysplastic syndrome; ARRY-380, a HER2 inhibitor in Phase 1 clinical trial for breast cancer; ARRY-797, a p38 inhibitor in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist in Phase 1 clinical trial for allergic inflammation. The company?s partnered drugs in clinical development comprise Selumetinib and AZD8330 MEK inhibitors for cancer in Phase 2 trial; MEK162 and MEK300 MEK inhibitors for cancer in Phase 2 trial; Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 trial; ARRY-543, a HER2/EGFR inhibitor in Phase 2 trial for solid tumors; and LY2603618, a ChK-1 inhibitor in Phase 2 trial for cancer. Its partnered drugs in clinical development also include AMG 151, a glucokinase activator in Phase 1b trial for Type 2 diabetes; GDC-0068, a AKT inhibitor in Phase 1b trial for cancer; VTX-2337, a toll-like receptor in Phase 1b trial for cancer; VTX-1463, a toll-like receptor in Phase 1b trial for allergy; ARRY-382, a cFMS inhibitor in Phase 1 trial for cancer; and ARRY-575 and GDC-0425, which are ChK-1 inhibitors in Phase 1 trial for cancer. The company has collaborations with Amgen, Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Genentech, Inc.; Novartis International Pharmaceutical Ltd.; InterMune, Inc.; Eli Lilly and Company; and VentiRx Pharmaceuticals, Inc for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Advisors' Opinion:- [By Dan Carroll]
Array's phase 2 study pays off big
It's tough to find a stock anywhere on the market that had as good a week as Array BioPharma (NASDAQ: ARRY ) . Shares of the biotech picked up nearly 17.8% on the week, part of a 63.5% gain year-to-date. The company's developmental drug to treat persistent allergic asthma, ARRY-502, hit the right marks in improving patient lung function in phase 2 trial results. Even better for investors, Array CEO said several other health companies have shown interest to help the company in development of ARRY-502. - [By Keith Speights]
Breathing easier
Array BioPharma (NASDAQ: ARRY ) shares climbed nearly 18% this week. The company announced positive results from a phase 2 study of its experimental asthma drug ARRY-502. - [By Sean Williams]
Shareholders "nudged" Array BioPharma (NASDAQ: ARRY ) higher by nearly 18% on the week after it announced positive mid-stage data on ARRY-502, a treatment for mild to moderate persistent allergic asthma. In its mid-stage trial, ARRY-502 met its primary endpoint of improving lung function as measured by forced expiratory volume in one second, or FEV1. In the overall trial, FEV1 increased by 3.9% compared to the placebo, while a specified subset of patients in the Th2 Biomarker group saw their FEV1 jump by 6.8% relative to the placebo. ARRY-502 also met a number of secondary endpoints. Since the asthma market is a crowded field, Array also put the feelers out there that it's looking for a licensing partner to help take this experimental drug into the next stage.
- [By Sean Williams]
Array BioPharma (NASDAQ: ARRY ) presented some particularly intriguing findings with its MEK inhibitor, selumetinib, which it has licensed out to AstraZeneca�to treat uveal melanoma (cancer of the eye). Historically this is a very difficult to treat disease, but initial studies of selumetinib more than doubled the time it took for the disease to progress compared to the current standard of treatment, temozolomide. In trials, selumetinib delivered 15.9 weeks without disease progression, an overall response rate of 50%, and major tumor shrinkage exhibited in 15% of patients. For temozolomide, steady disease was only established for a median of seven weeks with no tumor shrinkage present.�
Hot Net Payout Yield Stocks To Buy For 2014: Plantronics Inc.(PLT)
Plantronics, Inc., together with its subsidiaries, engages in the design, manufacture, and marketing of lightweight communications headsets, telephone headset systems, and accessories for the business and consumer markets under the Plantronics name worldwide. It also offers specialty telephone products, such as telephones for the hearing impaired and other related products for people with special communication needs under the Clarity brand name. The company?s products are designed for specific markets and applications, such as offices; contact centers; mobile devices comprising mobile phones and smart phones; computer and gaming; and residential applications, as well as for other specialty applications. It sells its products through a network of distributors, retailers, wireless carriers, original equipment manufacturers, and telephony service providers. The company was founded in 1961 and is headquartered in Santa Cruz, California.
Advisors' Opinion:- [By Sean Williams]
Can you hear me now?
Unlike YRC, which I consider to be in awful shape, audio communication solutions maker Plantronics (NYSE: PLT ) is merely a sell in my book based on its recent share price appreciation. - [By Lee Jackson]
Plantronics Inc. (NYSE: PLT) is a global leader in audio communications for businesses and consumers. It has pioneered new trends in audio technology, creating innovative products that allow people to simply communicate. From unified communication to Bluetooth headsets to gaming solutions, it delivers uncompromising quality, an ideal experience and extraordinary service. Plantronics is used by every company in the Fortune 100, as well as 911 dispatch, air traffic control and various mission critical applications for those on the frontline. Investors are paid a small 0.9% dividend. The J.P. Morgan target price is $49, and the consensus is set higher at $54.14. Plantronics closed Tuesday at $45.79.
Hot Net Payout Yield Stocks To Buy For 2014: Maxim Integrated Products Inc.(MXIM)
Maxim Integrated Products, Inc. engages in designing, developing, manufacturing, and marketing various linear and mixed-signal integrated circuits worldwide. The company also provides various high-frequency process technologies and capabilities for use in custom designs. It primarily serves industrial, communications, consumer, and computing markets. The company markets its products through a direct-sales and applications organization, as well as through its own and other unaffiliated distribution channels. Maxim Integrated Products, Inc. was founded in 1983 and is headquartered in Sunnyvale, California.
Advisors' Opinion:- [By rusticnomad]
Maxim Integrated (MXIM) didn't do very well last quarter as its revenue declined. This decline was anticipated by management, as its consumer business was facing seasonal weakness. However, the gains from the initial ramp of a new smartphone at its largest customer arrested the decline.
Hot Net Payout Yield Stocks To Buy For 2014: Israel Corporation Ltd (ILCO)
Israel Corporation Ltd is an Israel-based holding company. The Company operates mainly through its subsidiaries: Israel Chemicals Ltd, operating in the areas of fertilizers and special chemicals; Oil Refineries Ltd, engaged in crude oil refining, production of fuel products, raw materials for the petrochemical industry and materials for the plastics industry; ZIM Integrated Shipping Services Ltd, operating in the shipping lines��industry through use of tankers, offering delegation, Customs clearance, overland transport, distribution, warehousing, insurance, container terminals, marine terminal operation services and logistic services; I.C. Power Ltd, engaged in the production and sale of electricity, as well as in activities intended for the construction and operation of power stations, and Other subsidiaries, engaged in advanced technology, vehicles, infrastructures for electric-powered vehicles, and clean energy. Advisors' Opinion:- [By Claudia Maedler]
The DFM General Index (DFMGI) climbed 4.8 percent to 2,659.93, the highest close since Aug. 26. The measure had plunged as much as 15 percent since reaching a five-year high on Aug. 25 on concern the U.S. would launch a military strike against Syria. Emaar Properties PJSC (EMAAR), the stock with the biggest weighting on the index, jumped 4.7 percent, while Deyaar Development (DEYAAR) PJSC surged 9.1 percent. Israel Corp. (ILCO) led gains in Tel Aviv.
Hot Net Payout Yield Stocks To Buy For 2014: Reaves Utility Income Fund (UTG)
Reaves Utility Income Fund (the Fund) is a non-diversified, closed-end management investment company. The Fund's investment objective is to provide dividend income and capital appreciation. W.H. Reaves & Co., Inc. (Reaves) serves as the Fund's investment adviser. ALPS serves as the Fund's administrator. The Fund intends to invest at least 80% of its total assets in dividend-paying common and preferred stocks, and debt instruments of companies within the utility industry. The remaining 20% of its assets may be invested in other securities, including stocks, money market instruments and debt instruments, as well as certain derivative instruments in the utility industry or other industries.
During the fiscal year ended October 31, 2005 (fiscal 2005), the common stock of electric utilities averaged about 47% of the Fund's portfolio. The telephone sector, particularly rural telecom, was a significant source of dividend income for the Fund, with an average yield of 5.75% in fiscal 2005. Telecommunications common holdings averaged about 19% of the Fund's portfolio during fiscal 2005. Preferred stock holdings, yielding 6.9%, accounted for 8.5% of the Fund's portfolio as of October 31, 2005. The top five holdings of the Fund, as of October 31, 2005, were Duke Energy (7.1%), Ameren Corporation (5.8%), Altria Group (5.4%), Great Plains Energy (5.1%) and AT&T (4.1%).
Advisors' Opinion:- [By Harry Domash, Publisher, DividendDetective and Winning Investing]
Harry Domash: Well, one that's really good for us has been Reaves Utility Income. It holds primarily US utility and telecom stocks and it's been a pretty good dividend raiser. The ticker is (UTG), paying about a 6.1% yield now and it's a good serial dividend increaser so it's a very good one.
If you're worried about rising interest rates then Invesco Dynamic Credit Opportunities, ticker (VTA), invests in below investment-grade floating rate bank loans. In other words, these are called senior loans.
They're bank loans that adjust their payouts based on prevailing interest rates, so if interest rates go up, these loans will pay higher dividends, so this is a good hedge if you are concerned about rising interest rates.
Another one that's really performed, and it's paying a 6.9% yield right now, Guggenheim Strategic Opportunities, ticker (GOF), that's actually Claymore Guggenheim, holds corporate and government backed, that it's mostly investment-grade and it's paying a 10.1% yield right now, which is pretty high. Those are three that I could recommend right now.
Steven Halpern: Well, we really appreciate you joining us today and sharing your expertise. Thank you.
Harry Domash: You're welcome.
Subscribe to the Dividend Detective here...
Hot Net Payout Yield Stocks To Buy For 2014: Cullen/Frost Bankers Inc (CFR)
Cullen/Frost Bankers, Inc. (Cullen/Frost), incorporated in 1977, is a financial holding company and a bank holding company. The Company offers commercial and consumer banking services, as well as trust and investment management, mutual funds, Section 1031 property exchange services, investment banking, insurance, brokerage, leasing, asset-based lending, treasury management and item processing services. At December 31, 2011, Cullen/Frost had consolidated total assets of $20.3 billion. The Company operates in two segments: Banking and Frost Wealth Advisors. The Company serves a variety of industries including, among others, energy, manufacturing, services, construction, retail, telecommunications, healthcare, military and transportation. On January 1, 2012, the Company acquired Stone Partners, Inc., a Houston-based human resources consulting firm that specializes in compensation, benefits and outsourcing services. During the year ended December 31, 2011, the Company acquired an insurance agency in the San Antonio market area.
Cullen/Frost�� subsidiaries include The New Galveston Company, Cullen/Frost Capital Trust II (Trust II), The Frost National Bank (Frost Bank), Frost Insurance Agency, Inc., Frost Brokerage Services, Inc. (FBS), Frost Premium Finance Corporation, Frost Investment Advisors, LLC, Frost 1031 Exchange, LLC, Frost Securities, Inc. and Main Plaza Corporation. The Banking operating segment includes both commercial and consumer banking services, Frost Securities, Inc. and Frost Insurance Agency. Commercial banking services are provided to corporations and other business clients and include an array of lending and cash management products. Consumer banking services include direct lending and depository services. Frost Insurance Agency provides insurance brokerage services to individuals and businesses covering corporate and personal property and casualty products, as well as group health and life insurance products. Frost Securities, Inc. provides advisory and private equity s! ervices to middle market companies. The Frost Wealth Advisors operating segment includes fee-based services within private trust, retirement services, and financial management services, including personal wealth management and brokerage services. The parent company�� principal activities include the direct and indirect ownership of the Corporation�� banking and non-banking subsidiaries and the issuance of debt and equity.
The New Galveston Company
The New Galveston Company is a wholly owned second-tier financial holding company and bank holding company. The Company directly owns all of Cullen/Frost�� banking and non-banking subsidiaries with the exception of Cullen/Frost Capital Trust II.
Cullen/Frost Capital Trust II
Trust II is a business trust formed for the purpose of issuing trust preferred securities and lending the proceeds to Cullen/Frost. Trust II is a variable interest entity for which the Company is not the primary beneficiary.
The Frost National Bank
The Frost National Bank (Frost Bank) is primarily engaged in the business of commercial and consumer banking through approximately 115 financial centers across Texas in the Austin, Corpus Christi, Dallas, Fort Worth, Houston, Rio Grande Valley and San Antonio regions. At December 31, 2011, Frost Bank had consolidated total assets of $20.3 billion and total deposits of $16.8 billion. Frost Bank provides commercial banking services to corporations and other business clients. Loans are made for a variety of general corporate purposes, including financing for industrial and commercial properties and to a lesser extent, financing for interim construction related to industrial and commercial properties, financing for equipment, inventories and accounts receivable, and acquisition financing, as well as commercial leasing and treasury management services.
Frost Bank provides a range of consumer banking services, including checking accounts, savings progra! ms, autom! ated teller machines, overdraft facilities, installment and real estate loans, home equity loans and lines of credit, drive-in and night deposit services, safe deposit facilities, and brokerage services. Frost Bank provides international banking services to customers residing in or dealing with businesses located in Mexico. These services consist of accepting deposits, making loans, issuing letters of credit, handling foreign collections, transmitting funds, and to a limited extent, dealing in foreign exchange.
Frost Bank acts as correspondent for approximately 316 financial institutions, which are primarily banks in Texas. These banks maintain deposits with Frost Bank, which offers them a range of services, including check clearing, transfer of funds, fixed income security services, and securities custody and clearance services. Frost Bank provides a range of trust, investment, agency and custodial services for individual and corporate clients. These services include the administration of estates and personal trusts, as well as the management of investment accounts for individuals, employee benefit plans and charitable foundations. Frost Bank�� Capital Markets Division offers services, such as sales and trading, new issue underwriting, money market trading, and securities safekeeping and clearance.
Frost Insurance Agency, Inc.
Frost Insurance Agency, Inc. is a wholly owned subsidiary of Frost Bank. Frost Insurance Agency, Inc. provides insurance brokerage services to individuals and businesses covering corporate and personal property and casualty insurance products, as well as group health and life insurance products.
Frost Brokerage Services, Inc.
FBS is a wholly owned subsidiary of Frost Bank. FBS provides brokerage services and performs other transactions or operations related to the sale and purchase of securities of all types.
Frost Premium Finance Corporation
Frost Premium Finance Corporation is a who! lly owned! subsidiary of Frost Bank. Frost Premium Finance Corporation makes loans to qualified borrowers for the purpose of financing their purchase of property and casualty insurance.
Frost Investment Advisors, LLC
Frost Investment Advisors, LLC is a registered investment advisor entity and a wholly owned subsidiary of Frost Bank. Frost Investment Advisors, LLC provides investors access to various Frost-managed mutual funds.
Frost 1031 Exchange, LLC
Frost 1031 Exchange, LLC is a wholly owned subsidiary of Frost Bank. Frost 1031 Exchange, LLC assists customers in structuring the exchange of property such that the transactions result in a tax-deferred exchange in compliance with Section 1031 of the Internal Revenue Code.
Frost Securities, Inc.
Frost Securities, Inc. is a wholly owned subsidiary of The New Galveston Company. Frost Securities, Inc. provides advisory and private equity services to middle market companies in Texas.
Main Plaza Corporation
Main Plaza Corporation is a wholly owned non-banking subsidiary of The New Galveston Company. Main Plaza Corporation occasionally makes loans to qualified borrowers.
Advisors' Opinion:- [By Jack Adamo]
Steve Halpern: Another new recommendation is Cullen/Frost Bankers (CFR). There you've been recommending the 5.375% Perpetual Preferred Series A (CFR-PA). Now, you call Cullen/Frost one of the best little banks in Texas. What makes this such an attractive issue?
No comments:
Post a Comment